Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · May 2004
Randomized Controlled Trial Clinical TrialA randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening.
Although colorectal cancer screening by using a fecal occult blood test (FOBT), flexible sigmoidoscopy, colonoscopy, or barium enema x-ray reduces the incidence of and death from colorectal cancer, the rate of colorectal cancer screening in the general population is low. We conducted a randomized trial consisting of direct mailing of FOBT kits to increase colorectal cancer screening among residents of Wright County, Minnesota, a community in which colorectal cancer screening was promoted. ⋯ Direct mailing of FOBT kits combined with follow-up reminders promotes more rapid increases in the use of FOBT and nearly doubles the increase in overall rate of adherence to colorectal cancer screening guidelines in a general population compared with a community-wide screening promotion and awareness campaign.
-
J. Natl. Cancer Inst. · May 2004
Randomized Controlled Trial Multicenter Study Clinical TrialRandomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
5-fluorouracil-based adjuvant chemotherapy after surgical resection of colon cancer is standard treatment. However, the choice of best delivery route--that is, systemic (i.e., intravenous or oral) or regional (i.e., intraportal, intraperitoneal, or hepatic arterial infusion)--has been controversial. In a randomized clinical trial of patients with colon cancer, we compared the benefits of chemotherapy delivered by these routes individually or in combination. ⋯ Overall and event-free survival rates were similar in all three arms. The combined regimen was no better than either single regimen alone.
-
J. Natl. Cancer Inst. · May 2004
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2. We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer. ⋯ Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clinically relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clinical trials.
-
J. Natl. Cancer Inst. · May 2004
Multicenter Study Clinical TrialResults of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of California at Los Angeles-Oncology Research Network (UCLA-ORN) and the Breast Cancer International Research Group (BCIRG) have conducted two phase II studies to evaluate docetaxel and trastuzumab in combination with either cisplatin or carboplatin for the treatment of women with advanced breast cancer that overexpresses HER2. ⋯ Combinations of docetaxel, a platinum salt, and trastuzumab are feasible and active in patients with advanced breast cancers that overexpress HER2. The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings.
-
J. Natl. Cancer Inst. · May 2004
Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents.
The basic region-leucine zipper protein c-Jun has been linked to cell proliferation, transformation, and apoptosis. However, a direct role for c-Jun in angiogenesis has not been shown. ⋯ DNAzymes targeting c-Jun may have therapeutic potential as inhibitors of tumor angiogenesis and growth.